Table 3.
Participants' Long-COVID clinical features. Data are presented as prevalence and frequency.
| Characteristics | Females |
Males |
Sig. |
|---|---|---|---|
| n = 151 | n = 62 | ||
| Persistent Fatigue | 55 (36.4%) | 22 (35.5%) | 0.961 |
| Persistent Respiratory Symptoms | 37 (24.5%) | 17 (27.4%) | 0.611 |
| Persistent Tinnitus | 4 (2.6%) | 2 (3.2%) | 0.802 |
| Persistent Vertigo | 7 (4.6%) | 3 (4.8%) | 0.93 |
| Persistent Headache | 22 (14.6%) | 2 (3.2%) | 0.08 |
| Persistent Visual Disturbances | 5 (3.3%) | 5 (8%) | 0.129 |
| Persistent Fever | 4 (2.6%) | 0 (0%) | 0.199 |
| Persistent Paresthesia | 15 (10.1%) | 10 (16.1%) | 0.244 |
| Persistent Myalgia/Joint Pain | 37 (35.5%) | 15 (24.2%) | 0.989 |
| Persistent Hyposmia/Anosmia | 50 (33.1%) | 20 (32.2%) | 0.964 |
| Persistent Palpitations | 5 (3.3%) | 2 (3.2%) | 0.99 |
| Persistent Gastrointestinal Tract Symptoms | 6 (3.9%) | 1 (1.6%) | 0.389 |
| Persistent Cognitive Deficits | 70 (46.3%) | 25 (40.3%) | 0.476 |
| Persistent Insomnia | 24 (15.9%) | 10 (16.1%) | 0.833 |
| Persistent Weakness | 5 (3.3%) | 2 (3.2%) | 0.987 |
| Persistent Mood Disturbances | 12 (7.9%) | 6 (9.6%) | 0.66 |